Pain

Latest News

Lasmiditan Increases Odds of Freedom From Migraine Attacks

Lasmiditan is associated with greater odds of achieving pain freedom from migraine attacks compared with placebo.

Fremanezumab Found to Reduce Number of Migraine Days in Patients With Chronic Migraine and Comorbid Depression

A pooled analysis evaluated reductions in migraine and headache days among patients with chronic migraine and comorbid depression in 2 placebo-controlled, phase 3 trials of fremanezumab.

Amygdala Connectivity May Predict CBT Efficacy for Adolescent Migraine

Connectivity between the amygdala and specific brain regions may predict headache reduction after cognitive behavioral therapy for adolescent migraine.

About 20 Percent of Women Avoid Pregnancy Due to Migraine

Migraine has a considerable impact on women’s pregnancy plans, with about 20 percent avoiding pregnancy due to migraine.

Effects of Anxiety and Depression on Pain Catastrophizing in Older Adults

The goal of the current study was to assess the potential role of anxiety and depression on pain catastrophizing in older adults with chronic pain.

FDA: Stimulation Trial Should Be Performed Before Implanting SCS for Pain

The FDA reported that between July 27, 2016 and July 27, 2020, a total of 107,728 medical device reports (MDRs) associated with SCS devices intended for pain were received.

Qdolo Approved for Pain Management

Qdolo contains tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin reuptake.

Effects of Migraine on Disability and Neurological Function in MS

Among patients with multiple sclerosis, a history of migraine may not be associated with worse disability or neurological function.

Peginterferon beta-1a or IM IFN beta-1a May Offer Treatment Benefits in MS

Patients with MS treated with peginterferon beta-1a or intramuscular interferon beta 1a may experience real world treatment benefits.

Increased Pain Medication Use in Patients With Relapse of Neuromyelitis Optica Spectrum Disorder

Patients with neuromyelitis optica spectrum disorder who experience relapses use more pain medication than non-relapsing patients.